OncoMatch/Clinical Trials/NCT06084962
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Is NCT06084962 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies DeepTag-GPRC5D Targeted CAR T-cells for relapse/refractory multiple myeloma.
Treatment: DeepTag-GPRC5D Targeted CAR T-cells — Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
including chemotherapy based on proteasome inhibitors (PIs)
Must have received: immunomodulatory agent
immunomodulatory agents (IMiDs)
Must have received: CD38 antibody
CD38 antibody
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 8 weeks before screening
Patients who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks before screening
Cannot have received: allogeneic stem cell therapy
Patients received allogeneic stem cell therapy
Cannot have received: anti-cancer chemotherapy or other medications
Exception: within 2 weeks before screening
Patients who received anti-cancer chemotherapy or other medications within 2 weeks before screening
Lab requirements
Blood counts
Lymphocyte count > 0.3×10e9/L; Neutrophils ≥ 0.5×10e9/L; Hemoglobin ≥ 60g/L; Platelet ≥ 30×10e9/L
Kidney function
Creatinine > 2.5 mg/dl [excluded]
Liver function
ALT / AST > 3 times of normal amounts, or bilirubin > 2.0 mg/dl [excluded]
Cardiac function
Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
The blood routine meets the following standards: Lymphocyte count > 0.3×10e9/L; Neutrophils ≥ 0.5×10e9/L; Hemoglobin ≥ 60g/L; Platelet ≥ 30×10e9/L; Creatinine > 2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin > 2.0 mg/dl [excluded]; Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06084962 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplantation, allogeneic stem cell therapy, anti-cancer chemotherapy or other medications disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages